Albireo Pharma is a biopharmaceutical company focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Co. is pursuing the development of its key product candidate, odevixibat, for patients with progressive familial intrahepatic cholestasis, a life-threatening genetic disorder affecting young children. Co. is also developing odevixibat in biliary atresia and in Alagille syndrome. Co.'s product candidate in addition to odevixibat is elobixibat, which is approved in Japan for the treatment of chronic constipation. Co.'s key candidate for adult viral and liver diseases is A2342. The ALBO stock yearly return is shown above.
The yearly return on the ALBO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ALBO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|